Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

dc.contributor.authorGÜRSOY, PINAR
dc.contributor.authorTATLI, ALİ MURAT
dc.contributor.authorErdem, Dilek
dc.contributor.authorGÖKER, ERDEM
dc.contributor.authorCelik, Emir
dc.contributor.authorDemirci, Nebi Serkan
dc.contributor.authorSakin, Abdullah
dc.contributor.authorAtci, Muhammed Mustafa
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorAKIN TELLİ, TUĞBA
dc.contributor.authorBilgin, Burak
dc.contributor.authorBilici, Ahmet
dc.contributor.authorAkangunduz, Baran
dc.contributor.authorBALLI, SEVİNÇ
dc.contributor.authorDEMİRKAZIK, AHMET
dc.contributor.authorSelcukbiricik, Fatih
dc.contributor.authorMenekse, Serkan
dc.contributor.authorCavdar, Eyyup
dc.contributor.authorOzturk, Akin
dc.contributor.authorBekmez, Esma Turkmen
dc.contributor.authorTurhal, Serdal
dc.contributor.authorKilickap, Sadettin
dc.contributor.authorYILDIRIM, HASAN ÇAĞRI
dc.contributor.authorOyan, Basak
dc.contributor.authorAKSOY, ASUDE
dc.contributor.authorTurkoz, Fatma Paksoy
dc.contributor.authorKut, Engin
dc.contributor.authorKatgi, Nuran
dc.contributor.authorSakalar, Teoman
dc.contributor.authorAkyol, Murat
dc.contributor.authorELLEZ, HALİL İBRAHİM
dc.contributor.authorTOPÇU, Atakan
dc.contributor.authorErdogan, Atike Pinar
dc.contributor.authorPilanci, Kezban Nur
dc.contributor.authorHedem, Engin
dc.contributor.authorArak, Haci
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorAlan, Ozkan
dc.contributor.authorYapar, Burcu
dc.contributor.authorNART, DENİZ
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.institutionauthorTOPÇU, ATAKAN
dc.description.abstractObjectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study. Results EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p = 0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p = 0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically different than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p = 0.323). Conclusion In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options.
dc.identifier.citation-Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study-, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022
dc.titleReal-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
local.publication.goal03 - Sağlık ve Kaliteli Yaşam